

Neonatal Component

What's New in the Late-Onset Sepsis and Meningitis Event Module?


LaTasha R. Boswell RN, BSN, MPH, CIC NHSN Protocol and Training Team

March 2023

Objectives

- Locate the resources for Latenset Sepsis/Meningitis surveillance.
- Summarize the details of LateOnset Sepsis and Meningitis events.
- Describe updates related to the protocol and module.
- Identify resources required for LateOnset Sepsis/Meningitis module implementation.


NHSN Component Structure



Late-Onset Sepsis/Meningitis


Resources

Neonatal Component Website




https://www.cdc.gov/nhsn/neonatal/index.html

Late-Onset Sepsis/Meningitis Protocol Website




https://www.cdc.gov/nhsn/neonatal/los-men/index.html

Late-Onset Sepsis/Meningitis FAQ's



https://www.cdc.gov/nhsn/faqs/faq -losmen.html

Neonatal Component Training



https://www.cdc.gov/nhsn/training/neonatal/index.html

Late-Onset Sepsis/Meningitis

Surveillance Details

Surveillance Settings

- Level II/III Intermediate or Step Down Neonatal Intensive Care Units
- Level III Neonatal Intensive Care Units
- Level IV Neonatal Intensive Care Units

Eligible Infant

- Inpatient > 2 days,
- Housed on a Level II/III, Level III, or Level IV location
- Birth Weight 401 to 1500 grams
- DOL 4 -120
 - Birth Date = DOL 1, regardless of the time of birth

Late-Onset Sepsis (LOS)

Neonatal Laboratory-Confirmed Bloodstream Infection 1 (NLCBI 1)

Neonatal Laboratory-Confirmed Bloodstream Infection 2 (NLCBI 2)

Meningitis (MEN)

Neonatal Laboratory-Confirmed Meningitis 1 (NLCM 1)

Neonatal Laboratory-Confirmed Meningitis 2 (NLCM 2)

Late-Onset Sepsis Events (NLCBI 1)

Criterion	Neonatal Laboratory-Confirmed Bloodstream Infection (NLCBI)
	Comments and reporting instructions that follow the site-specific criteria provide further explanation and are integral to the correct application of the criteria. Must meet one of the following criteria:
NLCBI 1	An eligible infant with a recognized pathogen (specifically a bacterial or fungal organism which is not on the Common Commensals tab of the NHSN Organisms List) identified from one or more blood specimens by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing).
	OR
NLCBI 2	An eligible infant with a common commensal (specifically, a bacterial organism which is on the Common Commensal tab of the NHSN Organisms List) identified from one or more blood specimens by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing). AND Treatment is initiated during the LOS/MEN Window Period, on or after DOL 4 with one or more new intravenous (IV) antimicrobial agent(s)*. * New IV antimicrobial agent: Defined as any agent for which all 4 of the following are true: 1. Is listed in Table 6. 2. The antimicrobial "start date", which is the date of antimicrobial initiation, must occur sometime within the LOS/MEN Window Period, which is 2 calendar days before, the day of, or within 2 calendar days after the specimen collection date. 3. Antimicrobial start date must occur on or after DOL 4 with one or more new intravenous (IV) antimicrobial agent*(s) and continued for 5 or more qualifying antimicrobial days (QADs). Days between administrations of a new antimicrobial agent also count as QADs provided there is a gap of no more than 1 calendar day between administrations. 4. Was NOT given to the patient on either of the 2 days preceding the first antimicrobial initiated in the LOS/MEN Window Period current start date. (See Table 5: Examples of the Use of Antimicrobials Days and the LOS/MEN Window Period.)
	Note: Substitution of a different antimicrobial agent from <u>Table 6</u> within the LOS/MEN Window Period due to therapy/organism sensitivity factors will continue to meet the requirements for QADs.

NLCBI 1

In eligible infant with a recognized pathogen (specifically a bacterial or fungal organism which is not on the Common Commensals tab of the NHSN Organisms List) identified from one or more blood specimens by a culture or nonculture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing).

Late-Onset Sepsis Events (NLCBI 2)

Table 3: Neonatal Laboratory-Confirmed Bloodstream Infection Criteria			
Criterion	Neonatal Laboratory-Confirmed Bloodstream Infection (NLCBI)		
	Comments and reporting instructions that follow the site-specific criteria provide further explanation and are integral to the correct application of the criteria. Must meet one of the following criteria:		
	0		
NLCBI 1	An eligible infant with a recognized pathogen (specifically a bacterial or fungal organism which is not on the Common Commensals tab of the NHSN Organisms List) identified from one or more blood specimens by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing).		
	OR		
NLCBI 2	An eligible infant with a common commensal (specifically, a bacterial organism which is on the Common Commensal tab of the MHSN Organisms Ust) identified from one or more blood specimens by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing). AND Treatment is initiated during the LOS/MEN Window Period, on or after DOL 4 with one or more new intravenous (IV) antimicrobial agent(s)*. * New IV antimicrobial agent: Defined as any agent for which all 4 of the following are true: 1. Is listed in Table 6. 2. The antimicrobial "start date", which is the date of antimicrobial initiation, must occur sometime within the LOS/MEN Window Period, which is 2 calendar days before, the day of, or within 2 calendar days after the specimen collection date. 3. Antimicrobial start date must occur on or after DOL 4 with one or more new intravenous (IV) antimicrobial agent*(s) and continued for 5 or more qualifying antimicrobial days (2ADs). Days between administrations of a new antimicrobial agent also count as QADs provided there is a gap of no more than 1 calendar day between administrations. 4. Was NOT given to the patient on either of the 2 days preceding the first antimicrobial initiated in the LOS/MEN Window Period current start date. (See Table 5: Examples of the Use of Antimicrobials Days and the LOS/MEN Window Period due to therapy/organism sensitivity factors will continue to meet the requirements for		
	Period due to therapy/organism sensitivity factors will continue to meet the requirements for QADs.		

NLCBI 2

An eligible infant with a common commensal (specifically, a bacterial organism which is on the Common Commensal tab of the NHSN Organisms List) identified from one or more blood specimens by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing).

<u>AND</u>

Treatment is initiated during the LOS/MEN Window Period, on or after DOL4 with one or more new intravenous (IV) antimicrobial agent(s)*

Meningitis Events (NLCM 1)

Гable 4: Neo	natal Laboratory-Confirmed Meningitis Criteria
Criterion	Neonatal Laboratory-Confirmed Meningitis (NLCM) Comments and reporting instructions that follow the site-specific criteria provide further explanation and are integral to the correct application of the criteria.
	Must meet one of the following criteria:
NLCM 1	An eligible infant with a recognized pathogen (specifically, a bacterial or fungal organism which is not on the Common Commensal tab of the NHSN Organisms List) identified from a CSF specimen by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing).
	OR
NLCM 2	An eligible infant with a common commensal (specifically, a bacterial organism which is on the Common Commensal tab of the NHSN Organisms List) identified from a CSF specimen from one or more CSF specimens by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing). AND Treatment is initiated during the LOS/MEN Window Period, on or after DOL 4 with one or more new intravenous (IV) antimicrobial agent(s)*. * New IV antimicrobial agent: Defined as any agent for which all 4 of the following are true: 1. Is listed in Table 6. 2. The antimicrobial "start date", which is the date of antimicrobial initiation, must occur sometime within the LOS/MEN Window Period which includes 2 calendar days before, the day of, or within 2 calendar days after the specimen collection date. 3. Antimicrobial start date must occur on or after DOL 4 with one or more new intravenous (IV) antimicrobial agent*(s) and continued for 5 or more qualifying antimicrobial days (QADs). Days between administrations of a new antimicrobial agent also count as QADs provided there is a gap of no more than 1 calendar day between administrations. 4. Was NOT given to the patient on either of the 2 days preceding the first antimicrobial initiated in the LOS/MEN Window Period.) Note: Substitution of a different antimicrobial agent from Table 6 within the LOS/MEN Window Period due to therapy/organism sensitivity factors will continue to meet the requirements for QADs.

NLCM 1

An eligible infant with a recognized pathogen (specifically, a bacterial or fungal organism which is not on the Common Commensal tab of the NHSN Organisms List) identified from a CSF specimen by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing).

Meningitis Events (NLCM 2)

Table 4: Neonatal Laboratory-Confirmed Meningitis Criteria			
Criterion	Neonatal Laboratory-Confirmed Meningitis (NLCM)		
	Comments and reporting instructions that follow the site-specific criteria provide further explanation and are integral to the correct application of the criteria.		
NLCM 1	Must meet one of the following criteria:		
NICM 1	An eligible infant with a recognized pathogen (specifically, a bacterial or fungal organism which is not on the Common Commensal tab of the NHSN Organisms List) identified from a CSF specimen by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing).		
	OR		
NLCM 2	An eligible infant with a common commensal (specifically, a bacterial organism which is on the Common Commensal tab of the <a 2="" after="" antimicrobial="" before,="" calendar="" collection="" date="" date",="" date.<="" day="" days="" href="https://www.nisusus.gov/mensus.go</th></tr><tr><th></th><th>AND</th></tr><tr><th></th><th>Treatment is initiated during the LOS/MEN Window Period, on or after DOL 4 with one or more new intravenous (IV) antimicrobial agent(s)*.</th></tr><tr><th></th><th>* New IV antimicrobial agent: Defined as any agent for which all 4 of the following are true:</th></tr><tr><th></th><th> Is listed in <u>Table 6</u>. The antimicrobial " includes="" initiation,="" is="" li="" los="" men="" must="" occur="" of="" of,="" or="" period="" sometime="" specimen="" start="" the="" which="" window="" within=""> 		
	 Antimicrobial start date must occur on or after DOL 4 with one or more new intravenous (IV) antimicrobial agent*(s) and continued for 5 or more qualifying antimicrobial days (QADs). Days between administrations of a new antimicrobial agent also count as QADs provided there is a gap of no more than 1 calendar day between administrations. 		
	 Was NOT given to the patient on either of the 2 days preceding the first antimicrobial initiated in the LOS/MEN Window Period. (See Table 5: Examples of the Use of Antimicrobials Days and the LOS/MEN Window Period.) 		
	Note: Substitution of a different antimicrobial agent from Table 6 within the LOS/MEN		
	Window Period due to therapy/organism sensitivity factors will continue to meet the		
	requirements for OADs.		

NLCM 2

An eligible infant with a common commensal (specifically, a bacterial organism which is on the Common Commensal tab of the NHSN Organisms List) identified from a from one or more CSF specimens by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing).

AND

Treatment is initiated during the LOS/MEN Window Period, on or after DOL4 with one or more new intravenous (IV) antimicrobial agent(s)*.

Late-Onset Sepsis/Meningitis

Updates

Protocol Updates



January 2023

Late Onset Sepsis / Meningitis Event

Table of Contents

ate Onset Sepsis / Meningitis Event	1
ntroduction:	1
Details	2
Definitions:	2
Table 1: Examples of Infants Eligible for Surveillance Once Admitted to the Facility	5
Figure 1: Decision Flow to Determine Eligible Infants for the LOS/MEN Denominator	6
Table 2: Examples of Patient Transfer within the Transfer Rule Timeframe	7
Fable 3: Neonatal Laboratory-Confirmed Bloodstream Infection Criteria	9
Fable 4: Neonatal Laboratory-Confirmed Meningitis Criteria	10
Table 5: Examples of the Use of Antimicrobials Days and the LOS/MEN Window Period	11
Table 6: List of Intravenous Antimicrobials Eligible to Cite an NLCBI 2 or NLCM 2 Event	14
Figure 2: Guidance for Determination of LOS and MEN Events	15
/alidation:	
Data Analysis:	17
Appendix A – CDC Location Label	18

Introduction:

Late onest sepsis (LOS) and Meningitis (MEN) are common complications of extreme prematurity, Studies have indicated that 36% of extremely low gestational age (22-28 weeks) infants develop LOS and 21% of very low birth weight (VLBW) infants surviving beyond three days of life (DOL) will develop LOS. Another study found that meningitis occurs in 23% of bacteremic infants while 38% of infants with a pathogen isolated from the cerebrospinal fluid (CSF) may not have an organism isolated from blood. These infections are usually serious, causing a prolonged hospital stay and increased risk of mortality.³

Some cases of LOS can be prevented through proper central line insertion and maintenance practices. These are addressed in the CDC's Healthcare Infection Control Practices Advisory Committee

(CDC/HICPAC) <u>Guidelines for the Prevention of Introvasculor Cotheter-Related Infections</u>, 2011. However, in a quality improvement study, almost one-third of LOS events were not related to central-lines. Prevention strategies for these non-central line-related infection events have yet to be fully defined, but include adherence to hand-hygiene, parent and visitor education, and optimum nursery design features. Other areas that likely influence the development of LOS include early enteral nutritional support and skin care practices. ^{6,5}

4 EE

2023 Updates

- Minimal changes
- Revisions made for clarity
 - Example:
 - "> DOL3 and < 121" changed to "DOL4-120"

Validation Protocol Section Added - 2023

Validation:

LOS/MEN Synthetic Data Set (SDS):

LOS/MEN Protocol Page 16 & 17

An LOS/MEN Synthetic Data Set (SDS) was created to validate the software vendor or homegrown system's (homegrown system is a program created by the facility to capture and report data) uptake of LOS and MEN numerator and denominator data. An SDS, is a document of fake numerator and denominator data that is processed through the facility's electronic data collection system to ensure that data is accurately captured. The LOS/MEN SDS is comprised of 80 patients that test multiple positive and negative scenarios pertinent to the protocol. An answer key is provided for self-evaluation purposes. This validation process is optional but recommended upon initial implementation. To obtain the LOS/MEN SDS, contact NHSN@cdc.gov, Subject Line: LOS/MEN Synthetic Data Set.

https://www.cdc.gov/nhsn/pdfs/neonatal/losmen/los -men-protocol-508.pdf

Late-Onset Sepsis/Meningitis

Resources for Implementation

Resources for Implementation

- LOS/MEN CDA Toolkit: <u>https://www.cdc.gov/nhsn/cdaportal/toolkits.html#accordion-2-collapse-1</u> (Please click on the "Release 9.5 - January 2021" section)
- Late-Onset Sepsis/Meningitis Synthetic Data Set (optional): Available Upon Request at NHSN@cdc.gov, Subject: Late-Onset Sepsis/Meningitis Synthetic Data Set, Attn: LaTasha Boswell
- Late-Onset Sepsis/Meningitis Calculator (optional): Available Upon Request at NHSN@cdc.gov, Subject: Late-Onset Sepsis/Meningitis LOS/MEN Calculator, Attn: LaTasha Boswell

Summary

- Resources for the Late-Onset Sepsis/Meningitis event module are available below:
 - https://www.cdc.gov/nhsn/neonatal/index.html
 - https://www.cdc.gov/nhsn/neonatal/los-men/index.html
- The following events are available in the Late-Onset Sepsis/Meningitis module
 - LOS: NLCBI 1 & NLCBI 2
 - MEN: NLCM 1 & NLCM 2
- Updates:
 - Minimal changes made to the LOS/MEN protocol
 - 'Validation' section added to inform users of the SDS
- Resources available for LOS/MEN module implementation

Resources

- Neonatal Component website: https://www.cdc.gov/nhsn/neonatal/index.html
- Late-Onset Sepsis/Meningitis website: https://www.cdc.gov/nhsn/neonatal/los-men/index.html
- Neonatal Training Page: https://www.cdc.gov/nhsn/training/neonatal/index.html

For any questions or concerns, contact the NHSN Helpdesk at nhsn@cdc.gov

For more information please contact Centers for Disease Control and Prevention

1600 Clifton Road NE, Atlanta, GA30333

Telephone, 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348

E-mail: cdcinfo@cdc.gov Web: www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

